Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Development of an Online Patient Decision Aid for Previously Treated Mantle Cell Lymphoma

Thomas W. LeBlanc, MD MA, Robert C Wolf, PharmD, Ellen Neylon, NP, Valerie Caroselli, Katie Deering, Brad Schenkel, MSc

Blood (2015) 126 (23): 5634.

https://doi.org/10.1182/blood.V126.23.5634.5634

Published: 2015

Journal Articles

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Ahmed Sawas, MD, Joseph M. Connors, MD, John G. Kuruvilla, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Diego Villa, MDMPH, Michael Crump, MD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 586.

https://doi.org/10.1182/blood.V126.23.586.586

Published: 2015

Journal Articles

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma

Jennifer E Amengual, MD, Lichtenstein Renee, Celeste Rojas, Kelly Zullo, MS, Maximilian Lombardo, Emily Lichtenstein, RN, Ellen Neylon, NP, Changchun Deng, MD PhD, Ahmed Sawas, MD, Bijal D Shah, Catherine Wheeler, MD, Simon S Jones, PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 1280.

https://doi.org/10.1182/blood.V126.23.1280.1280

Published: 2015

Journal Articles

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

Owen A. O'Connor, MD PhD, Kelly Zullo, MS, Enrica Marchi, MD PhD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Donald Steven Colbourn, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Michael Smith, RN, Luigi Scotto, PhD, Jennifer E Amengual, MD

Blood (2015) 126 (23): 1282.

https://doi.org/10.1182/blood.V126.23.1282.1282

Published: 2015

Journal Articles

A Case Series Of Continuous Low Dose Lenalidomide In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

Ahmed Sawas, MD, Sean Clark-Garvey, MPH, Ellen Neylon, FNP, MSN, RN, OCN, Ameet Narwal, MPH, Kathleen Maignan, FNP, Emily Lichtenstein, RN, Owen A. O'Connor, MD, PhD

Blood (2013) 122 (21): 5134.

https://doi.org/10.1182/blood.V122.21.5134.5134

Published: 2013

Journal Articles

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

Jennifer E. Amengual, Sean Clark-Garvey, Matko Kalac, Luigi Scotto, Enrica Marchi, Ellen Neylon, Paul Johannet, Ying Wei, Jasmine Zain, Owen A. O’Connor

Blood (2013) 122 (12): 2104–2113.

https://doi.org/10.1182/blood-2013-02-485441

Published: 2013

Journal Articles

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Jennifer E Amengual, MD, Sean Clark-Garvey, Matko Kalac, MD, PhD, Luigi Scotto, PhD, Enrica Marchi, MD, PhD, Celests Rojas, Ellen Neylon, FNP, MSN, RN, OCN, Paul M Johannet, Salvia Jain, MD, Jasmine M. Zain, MD, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 2725.

https://doi.org/10.1182/blood.V120.21.2725.2725

Published: 2012

Journal Articles

Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies,

Jasmine M. Zain, MD, Francine M. Foss, MD, Catherine S. Diefenbach, MD, Daniel Petrylak, MD, Ameet Narwal, Ellen Neylon, NP, RN, BSN, OCN, Poul Knoblauch, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 3710.

https://doi.org/10.1182/blood.V118.21.3710.3710

Published: 2011

Journal Articles

Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies.

Jasmine M. Zain, MD, Francine M Foss, MD, Johann S. de Bono, Ameet Narwal, Ellen Neylon, RN, BSN, OCN, George Blumenschein, U. Lassen, MD, Poul Knoblauch, Catherine S. Diefenbach, MD, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 1787.

https://doi.org/10.1182/blood.V116.21.1787.1787

Published: 2010

Journal Articles

Correlation Between Baseline Methylmalonic Acid Status and Mucositis Severity in the PROPEL Study: Implications for Vitamin Prophylaxis.

Barbara Pro, MD, Bertrand Coiffier, MD, Steven M. Horwitz, MD, Adam Boyd, PhD, Ellen Neylon, RN, Steven Fruchtman, MD, Owen A O'Connor, MD, PhD

Blood (2009) 114 (22): 1681.

https://doi.org/10.1182/blood.V114.22.1681.1681

Published: 2009

Journal Articles

Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions

Alexander G. Marneros, Marc E. Grossman, David N. Silvers, Sameera Husain, Gerard J. Nuovo, Barbara MacGregor-Cortelli, Ellen Neylon, Molly Patterson, Owen A. O'Connor, Jasmine M. Zain

Blood (2009) 113 (25): 6338–6341.

https://doi.org/10.1182/blood-2009-03-210989

Published: 2009

Journal Articles

A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients with Hematologic Malignancies.

Diane R. Mould, PhD, Kevin Sweeney, Stephen Duffull, Ellen Neylon, RN, Owen A. O’Connor, MD, PhD

Blood (2007) 110 (11): 1370.

https://doi.org/10.1182/blood.V110.11.1370.1370

Published: 2007

Journal Articles

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

John Gerecitano, MD, PhD, Carol Portlock, MD, Ariela Noy, MD, Paul Hamlin, MD, Craig Moskowitz, MD, David Straus, MD, Steven M. Horwitz, MD, Maria Lia Palomba, MD, Otilia-Liana Dumitrescu, MD, Jennifer Pappanicholaou, Ellen Neylon, Rachel Hamelers, Andrew Zelenetz, MD,PhD, Thomas J. Myers, MD, Anthony L. Boral, MD, Owen A. O’Connor, MD,PhD

Blood (2006) 108 (11): 2759.

https://doi.org/10.1182/blood.V108.11.2759.2759

Published: 2006

Journal Articles

Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

John Gerecitano, MD, PhD, Andre Goy, MD, Barbara MacGregor-Cortelli, OCN, Ellen Neylon, John Wright, MD, PhD, Dixie Esseltine, MD, David Schenkein, MD, Mithat Gonen, PhD, Owen A. O’Connor, MD, PhD

Blood (2005) 106 (11): 3334.

https://doi.org/10.1182/blood.V106.11.3334.3334

Published: 2005

NARROW

Development of an Online Patient Decision Aid for Previously Treated Mantle Cell Lymphoma

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

A Case Series Of Continuous Low Dose Lenalidomide In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Preliminary Results of An Ongoing Phase I Trial of Oral Belinostat a Novel Histone Deacetylase Inhibitor in Patients with Lymphoid Malignancies,

Interim Results of a Phase 1 Trial of An Oral Histone Deacetylase Inhibitor Belinostat In Patients with Lymphoid Malignancies.

Correlation Between Baseline Methylmalonic Acid Status and Mucositis Severity in the PROPEL Study: Implications for Vitamin Prophylaxis.

Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions

A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients with Hematologic Malignancies.

The Schedule Dependent Combination of Bortezomib (Bor) with Rituximab (R), Cyclophosphamide (C) and Prednisone (P) Produces Minimal Toxicity, Even at Relatively High Doses of Proteasome Inhibitor, in Patients with Relapsed/Refractory Indolent B-Cell Lymphomproliferative Disorders.

Drug-Induced Cutaneous Vasculitis in Patients with Non-Hodgkin’s Lymphoma Receiving Bortezomib: A Possible Surrogate Marker of Response.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only